These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 31562222

  • 21. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 22. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A.
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [Abstract] [Full Text] [Related]

  • 23. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

  • 24. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana A, Van Leeuwen PJ, van Oosterom MN, Van Leeuwen FWB, Emmett L, Stricker PD.
    J Nucl Med; 2022 Nov 15; 63(11):1659-1664. PubMed ID: 35241483
    [Abstract] [Full Text] [Related]

  • 25. Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
    Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    World J Urol; 2021 Jul 15; 39(7):2439-2446. PubMed ID: 33079250
    [Abstract] [Full Text] [Related]

  • 26. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, Oprea-Lager DE, Bekers EM, Vis AN.
    BJU Int; 2023 Mar 15; 131(3):330-338. PubMed ID: 36069585
    [Abstract] [Full Text] [Related]

  • 27. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb 15; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 28. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM.
    BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ, Lee SW, Ha HK.
    Urol Int; 2019 Aug 05; 102(1):27-36. PubMed ID: 30269140
    [Abstract] [Full Text] [Related]

  • 30. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
    Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J.
    World J Urol; 2020 Dec 05; 38(12):3085-3090. PubMed ID: 32103332
    [Abstract] [Full Text] [Related]

  • 31. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
    Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.
    J Nucl Med; 2017 Dec 05; 58(12):1949-1955. PubMed ID: 28637799
    [Abstract] [Full Text] [Related]

  • 32. Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study.
    Quarta L, Mazzone E, Cannoletta D, Stabile A, Scuderi S, Barletta F, Cucchiara V, Nocera L, Pellegrino A, Robesti D, Leni R, Zaurito P, Brembilla G, De Cobelli F, Samanes Gajate AM, Picchio M, Chiti A, Montorsi F, Briganti A, Gandaglia G.
    Eur J Nucl Med Mol Imaging; 2024 Oct 05; 51(12):3789-3798. PubMed ID: 38861182
    [Abstract] [Full Text] [Related]

  • 33. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
    Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM.
    Prostate Cancer Prostatic Dis; 2022 Mar 05; 25(1):65-70. PubMed ID: 34471231
    [Abstract] [Full Text] [Related]

  • 34. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.
    BJU Int; 2018 Nov 05; 122(5):783-793. PubMed ID: 29726071
    [Abstract] [Full Text] [Related]

  • 35. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients.
    Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, Barentsz JO, Nagarajah J, Gotthardt M.
    J Nucl Med; 2021 Sep 01; 62(9):1258-1263. PubMed ID: 33517328
    [Abstract] [Full Text] [Related]

  • 36. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb 01; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 37. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
    Meijer D, Donswijk ML, Bodar YJL, van Leeuwen PJ, Poel HGV, Vogel WV, Nieuwenhuijzen JA, Hendrikse NH, Oprea-Lager DE, Vis AN.
    J Nucl Med; 2021 Jul 01; 62(7):961-967. PubMed ID: 33158904
    [Abstract] [Full Text] [Related]

  • 38. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H.
    Semin Oncol Nurs; 2020 Aug 01; 36(4):151044. PubMed ID: 32723519
    [Abstract] [Full Text] [Related]

  • 39. Feasibility of Using a Novel Drop-In Gamma Probe for 99m Tc-PSMA-I&S-Guided Lymph Node Detection During Robot-Assisted Radical Prostatectomy for Primary Prostate Cancer.
    Harke NN, Fuhrmann C, Czerner C, Rudolf F, Ross TL, Katzendorn O, Bengel F, Kuczyk MA, Weiberg D, Derlin T.
    Clin Nucl Med; 2024 Oct 01; 49(10):948-952. PubMed ID: 38968541
    [Abstract] [Full Text] [Related]

  • 40. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.
    Wit EMK, KleinJan GH, Berrens AC, van Vliet R, van Leeuwen PJ, Buckle T, Donswijk ML, Bekers EM, van Leeuwen FWB, van der Poel HG.
    Eur J Nucl Med Mol Imaging; 2023 Jul 01; 50(9):2861-2871. PubMed ID: 37036490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.